









Markets
/
Stocks
/
nasdaq-inva
/

Innoviva Inc

INVA

18.550USD

-0.080-0.43%

Market hours （ET）Quotes delayed by 15 min

1.16BMarket Cap

LossP/E TTM



Innoviva Inc

18.550

-0.080-0.43%

Overview Company Financials

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.

Company Info

Ticker SymbolINVA

Company nameInnoviva Inc

IPO dateOct 05, 2004

CEOMr. Pavel Raifeld

Number of employees127

Security typeOrdinary Share

Fiscal year-endOct 05

Address1350 Old Bayshore Highway

CityBURLINGAME

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code94010

Phone16502389600

Websitehttps://www.inva.com/

Ticker SymbolINVA

IPO dateOct 05, 2004

CEOMr. Pavel Raifeld

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Mark A. Dipaolo, Esq.

Chairman of the Board

130.71K

+10.18%

Dr. Sarah J. Schlesinger, M.D.

Lead Independent Director

130.71K

+10.18%

Dr. Sapna Srivastava, Ph.D.

Independent Director

44.10K

+11.98%

Ms. Marianne Y. Zhen, CPA

Chief Accounting Officer

27.71K

-3.46%

Mr. Pavel Raifeld

Chief Executive Officer

12.60K

+8.03%

Mr. Stephen Basso

Chief Financial Officer

4.63K

+31.73%

Mr. Jules A. Haimovitz

Independent Director

Dr. Odysseas D. Kostas, M.D.

Director

Mr. Derek A Small

Independent Director

Name

Name/Position

Position

Shareholding

Change

Mr. Mark A. Dipaolo, Esq.

Chairman of the Board

130.71K

+10.18%

Dr. Sarah J. Schlesinger, M.D.

Lead Independent Director

130.71K

+10.18%

Dr. Sapna Srivastava, Ph.D.

Independent Director

44.10K

+11.98%

Ms. Marianne Y. Zhen, CPA

Chief Accounting Officer

27.71K

-3.46%

Mr. Pavel Raifeld

Chief Executive Officer

12.60K

+8.03%

Mr. Stephen Basso

Chief Financial Officer

4.63K

+31.73%

Revenue Breakdown

FY2025Q1

FY2024

No Data

By RegionUSD

Name

Revenue

Proportion

United States

88.63M

0.00%

By Business

By Region

No Data

Shareholding Stats

Updated: Sat, May 17

Shareholders

Shareholder Types

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

13.12%

The Vanguard Group, Inc.

10.01%

Dimensional Fund Advisors, L.P.

7.42%

Renaissance Technologies LLC

7.26%

Putnam Investment Management, L.L.C.

6.21%

Other

55.98%

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

13.12%

The Vanguard Group, Inc.

10.01%

Dimensional Fund Advisors, L.P.

7.42%

Renaissance Technologies LLC

7.26%

Putnam Investment Management, L.L.C.

6.21%

Other

55.98%

Shareholder Types

Shareholders

Proportion

Investment Advisor

45.92%

Investment Advisor/Hedge Fund

33.15%

Hedge Fund

23.37%

Research Firm

6.09%

Pension Fund

1.54%

Individual Investor

1.06%

Bank and Trust

0.43%

Sovereign Wealth Fund

0.19%

Venture Capital

0.10%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

494

70.23M

111.87%

-7.08M

2025Q1

503

69.52M

110.75%

-9.29M

2024Q4

492

73.18M

116.75%

-6.44M

2024Q3

487

75.41M

120.47%

-5.51M

2024Q2

492

75.89M

121.41%

-5.03M

2024Q1

502

75.85M

119.80%

-4.18M

2023Q4

494

74.97M

116.88%

-1.82M

2023Q3

486

71.34M

109.51%

-8.23M

2023Q2

482

72.90M

111.23%

-6.11M

2023Q1

482

72.87M

106.90%

-10.58M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

BlackRock Institutional Trust Company, N.A.

8.24M

13.12%

-285.10K

-3.34%

Mar 31, 2025

The Vanguard Group, Inc.

6.28M

10.01%

-16.60K

-0.26%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

4.66M

7.42%

-259.73K

-5.28%

Mar 31, 2025

Renaissance Technologies LLC

4.56M

7.26%

+295.50K

+6.93%

Mar 31, 2025

Putnam Investment Management, L.L.C.

3.90M

6.21%

-462.44K

-10.61%

Mar 31, 2025

Sarissa Capital Management, L.P.

2.82M

4.49%

-4.46M

-61.30%

Mar 31, 2025

State Street Global Advisors (US)

2.36M

3.77%

-94.90K

-3.86%

Mar 31, 2025

Systematic Financial Management, L.P.

2.07M

3.3%

+42.18K

+2.08%

Mar 31, 2025

Millennium Management LLC

1.68M

2.67%

+1.28M

+318.37%

Mar 31, 2025

American Century Investment Management, Inc.

1.68M

2.67%

+251.38K

+17.65%

Mar 31, 2025

Related ETFs

Updated: Sat, Aug 2

Name

Proportion

Invesco Pharmaceuticals ETF

2.84%

ETC 6 Meridian Small Cap Equity ETF

2.56%

First Trust Horizon Managed Vol Small/Mid ETF

2.39%

SPDR S&P Pharmaceuticals ETF

2.04%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.44%

Invesco S&P SmallCap Low Volatility ETF

1.25%

Acquirers Small and Micro Deep Value ETF

0.94%

VictoryShares US Small Mid Cap Value Momentum ETF

0.82%

Invesco S&P SmallCap Health Care ETF

0.79%

Pacer US Small Cap Cash Cows Growth Leaders ETF

0.76%

Invesco Pharmaceuticals ETF

Proportion2.84%

ETC 6 Meridian Small Cap Equity ETF

Proportion2.56%

First Trust Horizon Managed Vol Small/Mid ETF

Proportion2.39%

SPDR S&P Pharmaceuticals ETF

Proportion2.04%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proportion1.44%

Invesco S&P SmallCap Low Volatility ETF

Proportion1.25%

Acquirers Small and Micro Deep Value ETF

Proportion0.94%

VictoryShares US Small Mid Cap Value Momentum ETF

Proportion0.82%

Invesco S&P SmallCap Health Care ETF

Proportion0.79%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Proportion0.76%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

KeyAI

